The Daily News Now! Business

FB Financial’s upcoming earnings report could be a bellwether for regional banking, as investors brace for a potential revenue surge of 28.4%—a sharp jump from last year’s 8.6%—despite past misses and softer net interest income. While they narrowly beat EPS estimates, revenue fell short of forecasts, and analysts remain cautiously optimistic. As the first regional bank to report this season, their...

Subprime auto loans are in freefall, with delinquency rates hitting a 32-year high—worse than during the Great Recession. Lenders like America’s Car-Mart and companies such as OneMain Holdings and Credit Acceptance are reeling as borrowers with shaky credit struggle to pay, forcing lenders to tighten belts and investors to steer clear. This sector is a ticking time bomb for anyone still considerin...

The world’s turning wilder—wars, trade wars, and climate chaos are rewriting the rules of investing. Old safe havens like bonds? Not so safe anymore. With superpowers clashing and the U.S. pulling back from global leadership, portfolios face higher risks and less protection. Investors and policymakers are scrambling as economic uncertainty spikes. The playbook’s been tossed out—and nobody’s sure w...

Oklo’s stock plummeted 27% this year as nuclear startup hype cools, fueled by cash needs and regulatory delays on their Aurora reactor — still years from deployment — while AI-driven demand fades and share dilution worsens their financial outlook. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high...

SpaceX’s AI ambitions could turn a $500K investment into over $1.6M by 2030, fueled by massive scaling of computing, chip factories, and orbital data centers—according to Goldman Sachs’ bold forecast of $100B+ AI revenue. But with ongoing losses, potential stock dilution, and looming AI market risks, the path to this valuation is fraught with uncertainty. Listen in comfort: Get a discount on a Sol...

Interactive Brokers is soaring—up 35% this year—as global traders flock to its international trading platform, especially with new direct access to South Korea’s booming market. Customer accounts surged 31% to 4.75 million, driving 19% higher commissions and 17% more net interest income. With a razor-sharp 77% pre-tax profit margin, IBKR’s lean model and explosive growth are turning investors bull...

Nvidia’s stock may have jumped 12% this year, but its forward P/E has dropped — signaling it’s actually looking cheaper for new investors. Why? Because earnings are soaring faster than the stock price. With net income tripling year-over-year and strong AI chip demand driving future growth, Nvidia’s P/E has plunged from 40 to 23.2. While investors shouldn’t rely on one metric, the combination of ex...

U.S. military strikes Iran’s Revolutionary Guard in third round of airstrikes after Iran attacked a container ship in the Strait of Hormuz — now Iran has shut the strait to all ships, but the U.S. insists it will keep the vital waterway open for global energy flow, sparking a standoff over unresolved transit route disputes from a June agreement. Listen in comfort: Get a discount on a Soli Pillow:...

Intel’s facing a supply crunch that’s actually good for business—demand for their chips is exploding, especially in AI-driven server and laptop markets, and they’re raising prices with customers still lining up to pay. With AI shifting toward CPU-heavy workflows, Intel’s core processors are suddenly more valuable than ever. To tackle the shortage, they’re speeding up advanced chip production and l...

AbbVie just splashed $10.9 billion to buy Apogee Therapeutics, a bold move to supercharge its drug pipeline in atopic dermatitis and respiratory treatments—keeping its Dividend King crown secure since spinning off from Abbott in 2013. The strategy? Acquire high-potential candidates to fuel future revenue and maintain steady payouts. Beyond new drugs, AbbVie’s cash cow, Botox, proves its knack for...

Yosemite is rewriting the cancer treatment playbook—building startups from scratch using university research and philanthropy to de-risk bold ideas. They’re tackling the impossible: epigenetic gene editing and targeted cell delivery, even going after the elusive p53 gene. With pharma flush with cash and patent cliffs looming, the market’s primed for breakthroughs—like Revolution Medicines’ pancrea...

Container bookings into the US are surging to near-yearly highs, driven not just by tariffs but also by early-season restocking and resilient consumer demand. With the Supreme Court striking down previous tariffs and a 10% surcharge set to expire July 24, the administration is eyeing new trade laws like Section 301 for potential 12.5% duties. While shipping volumes suggest a rush to beat upcoming...

Global energy reserves are in deep deficit, and the market is pivoting from emergency releases to a mandatory rebuilding phase, driven by geopolitical instability that’s raising shipping costs and forcing nations to refuel their strategic stockpiles. The U.S. and other IEA members have tapped reserves as temporary loans—companies get oil now but must repay with more later—creating future demand an...

Warren Buffett’s secret weapon? The S&P 500 index fund—his decades-long bet that passive investing beats active management, and history proves him right. Over 10 years, it crushed the competition; over 20, it’s nearly guaranteed to outperform, even through wild market swings. But beware: its heavy reliance on big tech means rough patches if those giants stumble. And while it can’t beat the market,...

Warren Buffett’s 2014 investment blueprint—90% in a low-cost S&P 500 index fund like Vanguard’s—proves that simplicity beats complexity: over 85% of large-cap funds underperformed the index in the last decade, while a $5,000 Vanguard ETF investment grew to over $25,000 with dividends. Buffett’s strategy avoids emotional market swings, sidesteps the trap of buying high and selling low, and delivers...

The working class is redefining itself — and it’s no longer just blue-collar. Tech pros, six-figure earners, and college grads are flocking to socialist movements, driven by economic anxiety, inequality, and the crushing cost of living. Even with high salaries, many feel trapped, forced into side hustles and debt. AI layoffs and soaring tech valuations fuel the sense that capitalism is rigged — an...

CrowdStrike just split its stock to make shares more affordable, fueling investor interest as its price soars 69% this year amid surging demand for AI-powered cybersecurity. With half its customers now using six+ Falcon modules, the company’s AI-driven defenses are gaining traction — even if its high valuation deters value investors. For growth seekers, though, CrowdStrike’s position in a booming,...

AppLovin rockets ahead with a 59% revenue surge to $1.8 billion in Q1 2026, outpacing Fastly’s 20% growth to $173 million — a stark contrast in tech dominance, with AppLovin commanding higher valuations and Fastly’s stock dipping after downgraded 2026 forecasts, despite its solid margins. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: adve...

In your thirties, money moves fast — and it’s not just about earning more. Housing and transportation dominate your budget, with rent or mortgage payments averaging $1,537 and car-related costs hitting $1,187. Meanwhile, you’re also investing heavily in your future: retirement contributions and life insurance now outpace food at home — both clocking in over $1,000 monthly. Eating out adds $475, ut...

Home Depot and Lowe’s are battling it out in the home improvement arena, with Home Depot raking in nearly $40 billion in quarterly revenue versus Lowe’s $25 billion, while both face stock dips amid rising rates and a slow housing market—but Home Depot’s stock hit a 52-week low and Lowe’s saw a drop, creating buying opportunities: Home Depot’s price-to-sales ratio fell below 2, and Lowe’s boosted i...

The Roundhill Memory ETF is riding a memory supercycle fueled by AI’s hunger for high-bandwidth memory, driving up prices and profits for top chipmakers like Micron, Samsung, and SK Hynix. Despite a recent 20% drop from its peak, the ETF remains a concentrated bet on a demand surge that could last well past 2030, with companies locking in long-term deals to smooth out cyclical swings. Listen in co...

SpaceX just hit a major milestone—added to the Nasdaq-100, forcing ETFs and funds to buy in and potentially boosting its stock. But don’t get too excited: a wave of lock-up expirations is looming, starting soon after earnings and stretching through December, unleashing a flood of shares—possibly far more than the IPO—that could crush momentum. While index inclusion is a win, the looming sell-off i...

James Kihara, key accountant at Acadia Pharmaceuticals, just unloaded 11,421 shares — worth nearly $300K — marking his largest single sale ever, slashing his direct stake by nearly half. Done via a pre-approved trading plan, the move coincided with rising stock prices fueled by EU drug approval buzz. While insider selling can spark questions, this isn’t a sudden shift — it’s part of his ongoing, s...

When stocks drop, it doesn’t mean they’re a bargain—especially in biotech. Recursion Pharmaceuticals, using AI to accelerate drug discovery, is betting big on a potential cure for rare FAP disease, but the high-risk nature of drug development has shaken investor confidence. Meanwhile, Sarepta Therapeutics faces a grim reality after patient deaths linked to their Duchenne muscular dystrophy drug, n...

Everyday investors are flocking to AI-driven giants like Nvidia, Microsoft, and Meta—companies they know and trust—fueling a massive shift in the market as AI unlocks trillions in potential. But while the hype is real, experts warn: overconcentration in the “Magnificent Seven” could be risky. Diversification remains key to weathering any storm. Listen in comfort: Get a discount on a Soli Pillow: h...